Similar articles

• KRAS Mutation as a Resistance Mechanism to BRAF/MEK Inhibition in NSCLC.

  Niemantsverdriet M, Schuuring E, Elst AT, van der Wekken AJ, van Kempen LC, van den Berg A, Groen HJM. Niemantsverdriet M, et al. J Thorac Oncol. 2018 Dec;13(12):e249-e251. doi: 10.1016/j.jtho.2018.07.103. J Thorac Oncol. 2018. PMID: 30467046 No abstract available.
• Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC.

  Liu W, Yin Y, Wang J, Shi B, Zhang L, Qian D, Li C, Zhang H, Wang S, Zhu J, Gao L, Zhang Q, Jia B, Hao L, Wang C, Zhang B. Liu W, et al. Oncotarget. 2017 Jan 3;8(1):179-190. doi: 10.18632/oncotarget.10162. Oncotarget. 2017. PMID: 27329725 Free PMC article.
• KRAS and EGFR Mutations Differentially Alter ABC Drug Transporter Expression in Cisplatin-Resistant Non-Small Cell Lung Cancer.

  Jaromi L, Csongei V, Vesel M, Abdelwahab EMM, Soltani A, Torok Z, Smuk G, Sarosi V, Pongracz JE. Jaromi L, et al. Int J Mol Sci. 2021 May 20;22(10):5384. doi: 10.3390/ijms22105384. Int J Mol Sci. 2021. PMID: 34065402 Free PMC article.
• Drug Combinatorial Therapies for the Treatment of KRAS Mutated Lung Cancers.

  He H, Xu C, Cheng Z, Qian X, Zheng L. He H, et al. Curr Top Med Chem. 2019;19(23):2128-2142. doi: 10.2174/1568026619666190902150555. Curr Top Med Chem. 2019. PMID: 31475900 Review.
• The KRAS oncogene: past, present, and future.

  Kranenburg O. Kranenburg O. Biochim Biophys Acta. 2005 Nov 25;1756(2):81-2. doi: 10.1016/j.bbcan.2005.10.001. Epub 2005 Oct 25. Biochim Biophys Acta. 2005. PMID: 16269215 Review. No abstract available.